title: [Clinical significance of expressions of tumor markers in peripheral blood in non-small cell lung cancer].
abstract: OBJECTIVE
  To investigate the expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA in peripheral blood from the patients with non-small cell lung cancer and analyze their correlations with non-small cell lung cancer.
  
  
  METHODS
  The expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA were detected by nested reverse transcription-PCR assay in peripheral blood from the patients with non-small cell lung cancer (n = 120), benign pulmonary disease (n = 106) and from healthy subjects (n = 80) so as to further investigate their relationship with clinicopathological features and prognosis. Meantime we also examined the sensitivity, specificity and accuracy of combination detection.
  
  
  RESULTS
  The expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA in non-small cell lung cancer patients were 56.7%, 57.5%, 35.0%, higher than that of benign pulmonary disease (0.9%, 6.6%, 5.7%) and healthy groups (0, 3.8%, 0, all P < 0.05). The ROC curves indicated the sensitivity of combined detection was 84.3% and the specificity of combined detection was 94.6%. Univariate analysis revealed that the clinical stage, the ECOG score and the number of positive marker had significant association with overall survival (OS) (χ(2) = 67.928, 95.981, 60.285, all P = 0.000). Multivariate analysis indicated that the clinical stage, ECOG score and the number of positive marker was an independent prognostic factor each (HR = 2.866, 4.251, 1.845, all P = 0.000).
  
  
  CONCLUSIONS
  BJ-TSA-9, CK19 and Pre-proGRP mRNA may be the specific and sensitive markers to detect circulating tumor cells in the peripheral blood of non-small cell lung cancer patients.
authors.affiliation: Department of Oncology, PLA 309 Hospital, Beijing 100091, China.
authors.forename: Yi-mei
authors.initials: YM
authors.lastname: Qu
authors.forename: Guo-qing
authors.initials: GQ
authors.lastname: Liao
authors.forename: Peng-hui
authors.initials: PH
authors.lastname: Liu
authors.forename: Hong-mei
authors.initials: HM
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
authors.forename: Liang-liang
authors.initials: LL
authors.lastname: Li
authors.forename: Guo-qing
authors.initials: GQ
authors.lastname: Xie
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D053539:Keratin-19 / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009367:Neoplasm Staging; D010455:Peptides / Q000097:blood; D011379:Prognosis; D011498:Protein Precursors / Q000097:blood; D012333:RNA, Messenger / Q000235:genetics; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; C530220:FAM83A protein, human; D053539:Keratin-19; D009363:Neoplasm Proteins; D010455:Peptides; D011498:Protein Precursors; D012333:RNA, Messenger; C047897:gastrin-releasing peptide precursor